WESTBOROUGH, Mass.,
March 4, 2014 /PRNewswire/ --
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology
company focused on discovering, developing and commercializing
innovative therapies addressing major unmet medical needs using
RNA-targeted technologies, today announced that the Company's
President & CEO, Dr. Geert
Cauwenbergh, will present at the 26th Annual ROTH
Conference on Tuesday, March 11, 2014
at 4:30pm PST. Dr. Cauwenbergh
will discuss the development of RXI-109, a self-delivering RNAi
compound designed to reduce dermal scarring, as well as business
development opportunities with RXi's sd-rxRNA® technology
platform.
The webcast presentation will be available on the "Investors"
section of the Company's website, www.rxipharma.com.
The 26th Annual ROTH conference will feature
presentations from hundreds of growth companies and thousands of
management 1-on-1/small group meetings, one of the largest of its
kind in the U.S. This event is designed to provide investors with a
unique opportunity to gain insight into emerging growth companies
across a variety of sectors. The conference will take place
March 9-12, 2014 at The Ritz-Carlton,
Dana Point, CA.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi platform. Therapeutics that use RNA
interference, or "RNAi," have great promise because of their
ability to down-regulate the expression of a specific gene that may
be over-expressed in a disease condition. Building on the
pioneering work of scientific founder and Nobel Laureate Dr.
Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate,
RXI‑109, targets connective tissue growth factor (CTGF) to reduce
dermal scarring (fibrosis), entered into human clinical trials in
June 2012. For more information, please visit
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products and technologies.
Forward-looking statements about expectations and development plans
of RXi's products involve significant risks, and uncertainties:
risks that RXi may not be able to successfully develop its
candidates, or that development of RNAi-based therapeutics may be
delayed or not proceed as planned, or that we may not develop any
RNAi-based product; risks that the development process for our
product candidates may be delayed, risks related to development and
commercialization of products by our competitors, risks related to
our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or
organizations may assert patent rights preventing us from
developing our products. Actual results may differ from those
contemplated by these forward-looking statements. RXi does not
undertake to update forward-looking statements to reflect a change
in its views, events or circumstances that occur after the date of
this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
SOURCE RXi Pharmaceuticals Corporation